ClinConnect ClinConnect Logo
Search / Trial NCT06949462

Effectiveness of Large Language Model for Anaesthesia and Procedural Consent

Launched by SINGAPORE GENERAL HOSPITAL · Apr 28, 2025

Trial Information

Current as of July 09, 2025

Not yet recruiting

Keywords

Anaesthesia Informed Consent Large Language Model Artificial Intelligence

ClinConnect Summary

This clinical trial is studying a new tool called PEAR, which is an AI-driven chatbot designed to help patients understand the risks of anaesthesia before surgery. The goal is to see if using this chatbot is more effective than the traditional method of having a doctor explain the risks face-to-face. Many patients struggle to understand anaesthesia information due to language differences, time pressure, or varying communication styles from healthcare providers. By using PEAR, the hope is to improve communication and reduce anxiety for patients going into surgery.

To participate in this trial, you need to be an adult (at least 21 years old) who is scheduled for elective surgery that requires anaesthesia and is classified as having a low to moderate risk (ASA Physical Status I to III). You should be able to communicate in English, Mandarin, Malay, or Tamil and be willing to interact with the PEAR chatbot and complete some questionnaires. However, if you have more severe health issues, cognitive impairments, or if you are undergoing emergency surgery, you won't be able to participate. This study is not yet recruiting participants, but it's an exciting opportunity to help improve how patients learn about anaesthesia risks.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • - Adults (≥21 years old) undergoing elective surgery requiring anaesthesia
  • Classified as ASA Physical Status I to III
  • Able to provide informed consent
  • Able to communicate effectively in English, Chinese (Mandarin), Malay, or Tamil
  • Willing and able to complete questionnaires and interact with the PEAR chatbot (intervention arm)
  • Exclusion Criteria:
  • ASA Physical Status IV or above
  • Cognitive impairment or psychiatric conditions that may limit comprehension or communication
  • Non-literate patients or those unable to understand English, Chinese, Malay, or Tamil
  • Emergency surgery cases
  • Prior participation in the study (to prevent bias)

About Singapore General Hospital

Singapore General Hospital (SGH) is a leading academic medical center in Singapore, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SGH plays a pivotal role in conducting cutting-edge studies that aim to improve patient outcomes and enhance medical knowledge across various specialties. With a strong focus on collaboration and multidisciplinary approaches, SGH leverages its extensive resources and expertise to facilitate rigorous clinical trials, ensuring the highest standards of safety and efficacy in the development of new treatments and therapies.

Locations

Singapore, , Singapore

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported